The patient profile ChondroFiller injection suits best

For most people researching cartilage treatment, the first question is whether they are even eligible. With the ChondroFiller injection (CFI) pathway, the eligibility bar is deliberately broad.

The procedure is an ultrasound-guided outpatient injection — no surgical admission, no general anaesthetic, no theatre booking. The collagen scaffold is placed directly into the joint during a clinic appointment, typically lasting thirty to forty-five minutes. That delivery method changes who can be considered, because the product works by coating load-bearing joint surfaces rather than needing intact cartilage borders around a contained defect.

In practice, patients who tend to be well matched to the CFI pathway include those with:

• Osteoarthritis — across all severities, including Kellgren-Lawrence Grade IV ('bone on bone') presentations
• Post-traumatic cartilage damage — following an injury, fracture, or previous joint surgery
• Sports-related or overuse wear — repetitive loading that has thinned or degraded cartilage over time
• Age-related degeneration — generalised surface loss rather than a single focal defect
• Chronic synovial inflammation — persistent joint irritation that has not settled with conservative measures

Most candidates have already tried physiotherapy, activity modification, or symptomatic injections without sufficient relief, and MRI-confirmed cartilage damage has been established. Whether the joint is the knee, hip, ankle, shoulder, or another site, the clinical picture above is the starting point for assessment.

Why age and cartilage loss grade rarely exclude you

Two factors stop many cartilage repair procedures in their tracks: the patient's age and how far the joint has deteriorated. Neither carries the same weight on the ChondroFiller injection pathway.

The mechanism explains why. ChondroFiller is an acellular scaffold — it promotes the body's own repair processes through matrix-induced chondrogenesis, recruiting progenitor cells from the synovium and subchondral bone into the collagen matrix. Because it does not rely on healthy adjacent cartilage to supply those cells, Kellgren-Lawrence Grade IV ('bone on bone') is an explicit indication for the injection pathway rather than a contraindication.

Age follows the same logic. There is no published upper age limit for CFI, and independent evidence supports that position: a 2025 study in the Bone & Joint Journal (n=217, mean follow-up 6.8 years) found no significant difference in functional or pain outcomes between patients aged 50–69 and those under 50 following AMIC-family scaffold repair (Lysholm p=0.232; VAS pain p=0.299). The Jerosch et al. post-market clinical follow-up study reinforces this in the same broad population: a mean IKDC improvement of 32.4 points at three years — well above the 16.7-point minimum clinically important difference — confirms that the scaffold mechanism delivers sustained functional benefit even among patients with advanced wear who other regenerative options would typically decline.

Where disease is multi-compartmental or covers a wide surface area, two or three boxes of product may be needed. That is a dosing consideration, not an exclusion criterion.

When conservative care has done enough

Conservative care rarely fails all at once. Physiotherapy eases load, activity modifications reduce flare frequency, and short-term analgesia or a single viscosupplementation injection can provide a period of reasonable control. The clinical trigger for moving towards ChondroFiller injection is not a single dramatic deterioration but the point at which that control is no longer adequate — persistent pain, declining everyday function, or synovial inflammation that keeps returning despite a reasonable trial of non-surgical management.

MRI-confirmed cartilage damage, rather than plain radiograph grade alone, is what shifts a patient from symptom management into a candidacy discussion, because conventional X-ray can understate soft-tissue loss in the earlier stages of wear.

Equally important is what patients do not need to wait for. The pathway does not require end-stage disease: intervening while some cartilage surface remains may help preserve what is left, rather than allowing further degradation through repeated cycles of management that have stopped working. A consultant-led assessment at this stage — when symptoms persist and imaging confirms damage — is a reasonable and timely step, not a premature one.

What the consultant looks for in assessment

At a first consultation, the assessment moves through a structured sequence: imaging, clinical history, and joint mapping together determine the appropriate approach and volume of treatment.

The MRI scan carries the most analytical weight. The consultant examines the pattern, location, and extent of cartilage damage — which compartments are involved, how deep the lesion reaches, and whether wear is focal or distributed across the joint surface. Where available, onMRI™ AI-assisted analysis can quantify defect geometry to supplement that review. This imaging picture is what drives pathway selection between the injection route and the surgical option; without it, the decision cannot be made reliably.

Clinical history adds context the scan cannot provide: symptom duration, the trajectory of decline, which previous treatments have been tried, and how much everyday function has been lost.

Joint-specific factors — compartmental involvement, degree of synovial thickening, and limb alignment — feed into the dosing plan. Where disease spans multiple compartments or covers a wide surface, more product may be needed; as discussed above, that affects volume, not eligibility.

Regenerative capacity is evaluated individually at consultation rather than assumed from age or lifestyle. Because the scaffold works by recruiting the patient's own progenitor cells, the relevant question is biological — synovial health, subchondral bone signal, and systemic condition — not a number on a birth certificate.

Cases where a different pathway may be more appropriate

Not every presentation is a clean fit for the outpatient injection route, and a consultant-led pathway exists precisely to identify that.

Active joint infection is a standard contraindication across all injectable therapies. Patients with uncontrolled systemic inflammatory arthropathy — rheumatoid arthritis being the most common example — should raise this at the point of enquiry rather than assuming automatic exclusion: individual suitability is assessed at consultation rather than determined by diagnosis alone.

Where imaging shows a single, focal Grade III or IV defect with structurally intact surrounding cartilage borders, an arthroscopic delivery approach — Liquid Cartilage™ Surgery — may offer a better clinical match. That is a distinct surgical service and a separate conversation, not the outpatient injection pathway this article describes.

Published literature does not enumerate every absolute contraindication, and the consultant reviews individual cases against current evidence rather than a fixed exclusion list. Any patient for whom the injection pathway is not appropriate will be directed towards the right alternative at the assessment stage.

Booking an assessment at MSK Doctors

Booking a ChondroFiller injection assessment at MSK Doctors requires no GP referral and no NHS-style waiting list — patients can arrange a consultant appointment directly.

The principal sites for non-London patients are Sleaford, Lincolnshire (NG34), home of the Regeneration Hub and an on-site Open MRI scanner, and Grantham (NG31), which houses the consultation and diagnostics centre alongside the MFO Life Sciences Lab. Both centres offer the full assessment pathway described in the sections above.

MSK Doctors is CQC-registered and rated 'Good' across all five key domains, giving patients a clear benchmark for clinical governance before they book.

To arrange an assessment, visit mskdoctors.com.

1. [1] Patients aged 50–69 show comparable outcomes to those aged under 50 following AMIC for focal chondral defects. (2025). https://doi.org/10.1302/0301-620X.107B10.BJJ-2024-1397.R2 https://doi.org/10.1302/0301-620X.107B10.BJJ-2024-1397.R2